Santhanam Subramanian

The policy change will act as a very important and positive catalyst event for the company.

We remain confident of achieving an EBITDA breakeven in Q4, and significantly, meaningfully contribute to the bottom line EBITDA in the next year.

We are confident of achieving our internal target margin of 20% to 21% range in FY 2026.

We are on track to achieve our internal target of 21%-22% for the full year, which means effectively the second half should be better compared to the first half.

We are confident of achieving our overall internal EBITDA margin target of around 21%-22%, as mentioned during the last earnings call.

We expect to achieve around a 21%-22% EBITDA margin target set internally for the year.

We are confident of achieving 20% EBITDA margin target, set internally for the year, as mentioned in the previous quarter.

We have taken these aggressive measures because we believe it is the most responsible and appropriate course of action until we conduct investigation and assessment to give FDA assurance that we are addressing its observations.

Our endeavor is to achieve an internal target of 18+% EBITDA for the year, plus margin on special product.